Nanoparticles in Infectious Disease Control: Microbial Synthesis, Antimicrobial Mechanisms, and Therapeutic Innovations

The escalating threat of multidrug-resistant (MDR) pathogens has underscored the urgent need for innovative strategies to combat infectious diseases. Nanoparticles (NPs) have emerged as a versatile platform due to their unique physicochemical properties and potent antimicrobial capabilities. This review provides an in-depth analysis of NPs in infectious disease management, emphasizing their antimicrobial mechanisms, microbial synthesis, and therapeutic applications. Metal-based NPs, such as silver (AgNPs), zinc oxide (ZnO NPs), and copper oxide (CuO NPs), disrupt microbial cell membranes, generate reactive oxygen species (ROS), and inhibit biofilms, making them effective against bacteria, viruses, fungi, and parasites. Green synthesis using bacteria, fungi, and algae offers a sustainable, biocompatible approach to NP production, enhancing their suitability for medical applications. NPs improve drug delivery, overcome MDR, and support advanced therapies, including wound healing, antiviral treatments, vaccine development, and immunotherapy. This review also explores NP interactions with the microbiome, diagnostic applications, and specific bacterial infectious diseases—such as tuberculosis, pneumonia, urinary tract infections, skin infections, Helicobacter pylori infections, and Clostridium difficile infections along with their NP-based treatments. Challenges like toxicity, scalability, regulatory hurdles, and potential NP resistance are discussed, alongside future directions involving CRISPR and AI-driven NP design.